614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies II
Patrice Chevallier, Thibault Leguay, Michael Doubek, et al.
A very active and well-tolerated first-line therapy for older patients with CD22 + Ph-neg BCP-ALL is fractionated inotuzumab ozogamicin in reduced doses plus low-intensity chemotherapy.
Philippe Rousselot, Yves Chalandon, Sylvie Chevret, et al.
The combined administration of four cycles nilotinib plus chemotherapy have been shown to be very effective in bridging younger adults with Ph-positive ALL to SCT. If HD-AraC is omitted, the recurrence rate is higher despite the BCR-ABL1-MRD4 values that are non-inferior.
Nora Zieger, Maryam Kazerani Pasikhani, Tobias Straub, et al.
The study data suggest that TFI rejuvenates T cells (functionally and transcriptionally). After restimulation (day 21 TFI), T cells activate an effector program again. They are less exhausted compared to CONT-T cells. Further studies should identify gene clusters that are crucial for persistent T cell function. They might serve as targets that improve the efficacy of T-cell-based immunotherapies.
Kangyu Huang, Bingqing Tang, Zihong Cai, et al.
The study shows: The novel HDAC-selective inhibitor tucidinostat could specifically target the IKZF1del high-risk B-ALL by restoring IKZF1 expression. This would lead to a attenuation of the proliferation and a reversal of the Warburg effect and to an improvement in survival in the PDX model. A promising therapeutic strategy for B-ALL patients with changes in ICZF1 haploinsufficiency is emerging here.
Claire E. Pillsbury, Jairo A. Fonseca, Jodi Dougan, et al.
Siglec-15 is a novel, potent immunosuppressive molecule. It is active in the progression of leukemia and may be targeted to activate T lymphocytes against leukemia cells.
Andre Baruchel, Jonas Abrahamsson, Yves Bertrand, et al.
With a poor prognostic relapse rate, 7 out of 17 patients achieved CR + Cri (41.2%). The safety profile and exposure are consistent with the available adult data. Enrollment starts for patients under 2 years of age with R / R ALL or AML.